2020
DOI: 10.1186/s12906-020-03173-2
|View full text |Cite
|
Sign up to set email alerts
|

Comparative in vitro analysis of inhibition of rhinovirus and influenza virus replication by mucoactive secretolytic agents and plant extracts

Abstract: Background Rhinoviruses and influenza viruses cause millions of acute respiratory infections annually. Symptoms of mild acute respiratory infections are commonly treated with over-the-counter products like ambroxol, bromhexine, and N-acetyl cysteine, as well as of thyme and pelargonium extracts today. Because the direct antiviral activity of these over-the-counter products has not been studied in a systematic way, the current study aimed to compare their inhibitory effect against rhinovirus and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
13
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 12 publications
(15 citation statements)
references
References 45 publications
1
13
0
1
Order By: Relevance
“…Since clinical applications and repurposing approaches rely on low inhibitory concentrations, we determined IC50 values for SARS-CoV-2 in both cell lines. The EPs 7630-specific IC50 for SARS-CoV-2 inhibition was 0.48 μg/ml in VeroFM cells and 1.61 μg/ml in Calu-3 cells (Figure 1B, green) being well within non-cytotoxic ranges (Figure 1B, yellow) and highly comparable to previous studies (Michaelis et al, 2011;Walther et al, 2020). To verify the antiviral activity of EPs 7630 against newly emerging SARS-CoV-2 variants, we analyzed its impact on SARS-CoV-2 Alpha and SARS-CoV-2 Beta propagation, both of which were classified as variants of concern (VOC) by the World Health Organization (Abdool Karim and de Oliveira, 2021; Konings et al, 2021).…”
Section: Eps 7630 Inhibits Propagation Of Highly Pathogenic Coronaviruses In Non-cytotoxic Concentrationssupporting
confidence: 88%
“…Since clinical applications and repurposing approaches rely on low inhibitory concentrations, we determined IC50 values for SARS-CoV-2 in both cell lines. The EPs 7630-specific IC50 for SARS-CoV-2 inhibition was 0.48 μg/ml in VeroFM cells and 1.61 μg/ml in Calu-3 cells (Figure 1B, green) being well within non-cytotoxic ranges (Figure 1B, yellow) and highly comparable to previous studies (Michaelis et al, 2011;Walther et al, 2020). To verify the antiviral activity of EPs 7630 against newly emerging SARS-CoV-2 variants, we analyzed its impact on SARS-CoV-2 Alpha and SARS-CoV-2 Beta propagation, both of which were classified as variants of concern (VOC) by the World Health Organization (Abdool Karim and de Oliveira, 2021; Konings et al, 2021).…”
Section: Eps 7630 Inhibits Propagation Of Highly Pathogenic Coronaviruses In Non-cytotoxic Concentrationssupporting
confidence: 88%
“…In one study involving both viruses, thyme extract did not show anti-rhinovirus activity, but showed antiviral activity against the influenza virus. At non-cytotoxic concentrations, the extract reduced the cytopathic effect of influenza in a dose-dependent manner [ 129 ]. Some studies also showed promising anti-retroviral properties of thyme [ 130 , 131 ], suggesting it to possibly interfere with essential viral functions of HIV-1.…”
Section: Biological Activity Of Thymementioning
confidence: 99%
“…The lowest compound concentration that blocked the abrogation of hemagglutination represented the minimum neuraminidase inhibitory concentration. 39 Antibacterial Assays. Double-concentrated half-log dilutions of reference antibiotics (ampicillin and rifampicin) and test materials (MAF, MA60, compounds 2, 4, and 7) were prepared in brain-heartinfusion broth or Todd Hewith broth with yeast extract (all Carl-Roth GmbH) for S. aureus and S. pneumoniae, respectively.…”
Section: ■ Experimental Sectionmentioning
confidence: 99%